Oral CBD Did Not Outperform Hemp Seed Oil for Temporomandibular Myofascial Pain
A randomized trial did not show that the tested oral CBD regimen relieved temporomandibular myofascial pain better than hemp seed oil. Jaw function improved over time in both groups, which is different from demonstrating a CBD-specific benefit.
The tested treatment was specific
The single-center trial compared a sublingually administered CBD oil regimen with hemp seed oil over three months. The reported CBD dose was 20 mg daily. Participants had myofascial pain involving the masticatory muscles; the study was not a trial of every cause of jaw pain or every cannabis formulation.
The principal pain outcome was assessed at one month, with pain and jaw-function follow-up at later visits. These were patient-reported outcomes, rather than measurements of cannabinoid concentrations in blood or evidence about driving performance.
Improvement within a group was not superiority
The reported pain comparisons did not significantly favor CBD at the assessed time points. Both groups showed improvement on the jaw-function measure over time, but the between-group comparisons did not establish an additional CBD effect.
This is a common interpretive trap. A person may improve during treatment because of the treatment, expectations, natural fluctuation, other influences or some combination. Randomization makes the difference between groups especially important when asking what benefit can be attributed to CBD.
The null result has boundaries
The findings do not prove that all CBD doses, topical preparations or THC-containing combinations are ineffective for all orofacial conditions. They address the regimen, population, comparator and follow-up studied. Increasing a dose or changing a formulation would create a new clinical question, not reverse this trial’s result.
The authors identified limitations involving dose selection, sample size, follow-up and adherence assessment. The report also uses differing denominators in its efficacy and adverse-event presentation, so a single simple percentage should not be substituted for a careful account of who contributed to each analysis.
How to evaluate a treatment claim
A claim based on this paper should state the diagnosis, route, daily dose and comparator. It should distinguish pain from function and change over time from benefit beyond the comparator. The study received commercial product and financial support, another relevant part of evaluating its methods and interpretation.
For a different pain condition and treatment regimen, see our analysis of CBD added to paracetamol in knee osteoarthritis.
Primary research
Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial. Medical Cannabis and Cannabinoids (2026). DOI: 10.1159/000551040.
